Research and practice in thrombosis and haemostasis

· 23 papers in corpus
review 2026
doi:10.1016/j.rpth.2026.106818 ·PMID:42598146

Heavy menstrual bleeding (HMB) is prevalent, with consequences impacting quality of life from adolescence through adulthood. Several clinical tools have been developed to aid in HMB diagnosis, which must be coupled with a detailed menstrual…

other 2026
doi:10.1016/j.rpth.2026.103368 ·PMID:41732302

Data on heavy menstrual bleeding in women with very rare bleeding disorders, such as very rare coagulation factor deficiencies or severe inherited platelet disorders, are scarce. Heavy menstrual bleeding is a common health problem in premen…

review 2026
doi:10.1016/j.rpth.2025.103276 ·PMID:41536292

Von Willebrand disease (VWD) is the most common inherited bleeding disorder in the world. It is characterized by mucocutaneous bleeding, with heavy menstrual bleeding affecting the vast majority of girls and women with this condition. Howev…

other 2025
doi:10.1016/j.rpth.2025.102698 ·PMID:40129564

A state of the art lecture titled, "Addressing the Perimenopause: What's Blood Got to Do with It?" was presented at the International Society on Haemostasis and Thrombosis (ISTH) Congress in 2024. Perimenopause is when fluctuations of previ…

observational 2025
doi:10.1016/j.rpth.2025.103235 ·PMID:41334355

BACKGROUND: Heavy menstrual bleeding (HMB) is common in adolescents and may indicate a bleeding disorder. The pictorial blood loss assessment chart (PBAC) defines HMB as a score ≥150, while an elevated self-bleeding assessment tool (self-BA…

review 2025
doi:10.1016/j.rpth.2025.103167 ·PMID:41050634

Abnormal uterine bleeding (AUB) describes any bleeding from the uterus that deviates from the norm in terms of regularity, duration, or volume. AUB is a common condition that can significantly affect quality of life. Although inherited blee…

observational 2025
doi:10.1016/j.rpth.2025.102959 ·PMID:40709220

BACKGROUND: Heavy menstrual bleeding (HMB) is common in young women. It may lead to iron deficiency with or without anemia, decreased school, work, sport, and social participation, and may be the first sign of underlying bleeding disorders …

observational 2025
doi:10.1016/j.rpth.2025.102910 ·PMID:40636903

BACKGROUND: Antiplatelet therapy may affect menstrual blood loss in women of reproductive age. OBJECTIVES: To determine menstrual bleeding and related quality of life (QoL) in women on antiplatelet therapy. METHODS: We performed a cross-s…

other 2024
doi:10.1016/j.rpth.2024.102448 ·PMID:38953049
observational 2024
doi:10.1016/j.rpth.2024.102567 ·PMID:39391562

BACKGROUND: Women with von Willebrand disease (VWD) often face diagnostic delays, leading to increased bleeds, stress, and healthcare use. The factors influencing these delays and their effects on gynecologic outcomes are not well understoo…

review 2024
doi:10.1016/j.rpth.2024.102444 ·PMID:38988949

BACKGROUND: The treatment landscape for relapsed or refractory immune thrombocytopenia (ITP) after corticosteroids is complex. OBJECTIVES: We aimed to assess the efficacy of danazol in treating ITP and evaluate the safety and adverse event…

observational 2023
doi:10.1016/j.rpth.2023.102229 ·PMID:38077824

BACKGROUND: Heavy menstrual bleeding (HMB), self-reported by 37% of adolescents, can be the first sign of a bleeding disorder (BD) during adolescence. The Dutch general practitioner (GP) guideline demands laboratory diagnostics and referral…

observational 2023
doi:10.1016/j.rpth.2023.100072 ·PMID:36861116

BACKGROUND: There is increasing recognition that menstruating women prescribed anticoagulants experience heavy menstrual bleeding. OBJECTIVES: The aim of this study is to report the extent of bleeding in menstruating women after commencing…

other 2023
doi:10.1016/j.rpth.2023.102244 ·PMID:38193051

Dr Erik von Willebrand first described a family with bleeding symptoms in a Finnish publication in 1926. A closer look at this landmark publication sheds light on some pathophysiological aspects of von Willebrand disease that may be applica…

2022
other 2022
doi:10.1002/rth2.12700 ·PMID:35441121

BACKGROUND: Recent reports have highlighted patients with COVID-19 and vaccine recipients diagnosed with coagulation factor inhibitors. This is challenging. as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been …

review 2022
doi:10.1002/rth2.12763 ·PMID:36032216

BACKGROUND: Venous thromboses are well-established complications of hormonal therapy. Thrombosis risk is seen with both hormonal contraceptive agents and with hormone replacement therapy for menopause and gender transition. Over the past se…

2022
2021
rct 2021
doi:10.1002/rth2.12474 ·PMID:33733030

BACKGROUND: Rivaroxaban may induce heavy menstrual bleeding. It is unknown if this effect is dose related or if rivaroxaban is associated with more menstrual bleeding than aspirin. OBJECTIVES: To demonstrate and compare menstrual patterns …

review 2021
doi:10.1002/rth2.12512 ·PMID:33977211

Direct oral anticoagulants (DOACs) are replacing warfarin and other vitamin K antagonists for a wide range of indications. Advantages of DOAC therapy are fewer food and drug interactions and fixed dosing without routine laboratory monitorin…

2020
observational 2020
doi:10.1002/rth2.12281 ·PMID:31989090

BACKGROUND: Patients with congenital blood platelet disorders (CPDs) demonstrate a predominantly mucocutaneous bleeding tendency. Repeated bleeds throughout life can have a significant impact on health status-related quality of life (HR-QoL…